Release No 37/2009 Affitech Issues Update on Litigation Copenhagen and Oslo, December 17th, 2009 Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that the ongoing litigation with a minority group of shareholders has been returned to the Lyngby court with a finding in favour of the litigants. This finding was reached on a technical matter - the late filing of Affitech's response - and not on a consideration of the merits of the litigants' claims or the Company's response to them. The Company expects Affitech's response to now be considered by the Lyngby court. As stated previously in the Company's June 30th prospectus document, Affitech and its advisors continue to believe that there is no legal basis for the objections filed in the minority shareholders' writ and the Company intends to defend its position vigorously. For more information please contact: Affitech: Robert F Burns, PhD CEO Tel # +45 50 99 76 42 About Affitech Affitech AS is a publically traded (Nasdaq OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.